FR2799123B1 - Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition - Google Patents

Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition

Info

Publication number
FR2799123B1
FR2799123B1 FR0010748A FR0010748A FR2799123B1 FR 2799123 B1 FR2799123 B1 FR 2799123B1 FR 0010748 A FR0010748 A FR 0010748A FR 0010748 A FR0010748 A FR 0010748A FR 2799123 B1 FR2799123 B1 FR 2799123B1
Authority
FR
France
Prior art keywords
composition
disagregent
aqueous medium
pharmaceutical composition
acid sensitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0010748A
Other languages
English (en)
Other versions
FR2799123A1 (fr
Inventor
Bruijn Karel De
Gunter Engel
Hans Jurgen Pfannkuche
Michael Thewissen
Christian Vitzling
Othmar Zuger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2799123(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2799123A1 publication Critical patent/FR2799123A1/fr
Application granted granted Critical
Publication of FR2799123B1 publication Critical patent/FR2799123B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR0010748A 1998-08-21 2000-08-21 Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition Expired - Lifetime FR2799123B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds

Publications (2)

Publication Number Publication Date
FR2799123A1 FR2799123A1 (fr) 2001-04-06
FR2799123B1 true FR2799123B1 (fr) 2005-12-02

Family

ID=27451823

Family Applications (3)

Application Number Title Priority Date Filing Date
FR9910666A Expired - Lifetime FR2782454B1 (fr) 1998-08-21 1999-08-20 Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition.
FR9914897A Expired - Lifetime FR2784899B1 (fr) 1998-08-21 1999-11-26 Agoniste, agoniste partiel ou antagoniste du recepteur 5-ht4 ou un sel pharmaceutiquement acceptable de ceux-ci pour utilisation dans la fabrication d'une composition pharmaceutique, y compris a usage veterinaire
FR0010748A Expired - Lifetime FR2799123B1 (fr) 1998-08-21 2000-08-21 Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FR9910666A Expired - Lifetime FR2782454B1 (fr) 1998-08-21 1999-08-20 Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition.
FR9914897A Expired - Lifetime FR2784899B1 (fr) 1998-08-21 1999-11-26 Agoniste, agoniste partiel ou antagoniste du recepteur 5-ht4 ou un sel pharmaceutiquement acceptable de ceux-ci pour utilisation dans la fabrication d'une composition pharmaceutique, y compris a usage veterinaire

Country Status (30)

Country Link
US (4) US20030236183A1 (fr)
EP (1) EP1104289B1 (fr)
JP (1) JP4048024B2 (fr)
KR (1) KR100529659B1 (fr)
CN (2) CN1589906A (fr)
AT (1) ATE316782T1 (fr)
AU (4) AU762829B2 (fr)
BG (1) BG65322B1 (fr)
BR (1) BR9913135A (fr)
CA (1) CA2338794C (fr)
CZ (1) CZ300647B6 (fr)
DE (1) DE69929703T2 (fr)
DK (1) DK1104289T3 (fr)
EE (1) EE05054B1 (fr)
ES (1) ES2257869T3 (fr)
FR (3) FR2782454B1 (fr)
HK (1) HK1038179A1 (fr)
HR (1) HRP20010123B1 (fr)
HU (1) HU228179B1 (fr)
ID (1) ID28510A (fr)
IL (1) IL141236A0 (fr)
IS (1) IS2369B (fr)
IT (1) IT1314185B1 (fr)
NO (1) NO328756B1 (fr)
NZ (1) NZ509832A (fr)
PL (2) PL200132B1 (fr)
RS (1) RS50104B (fr)
SK (1) SK285255B6 (fr)
TR (3) TR200400187T2 (fr)
WO (1) WO2000010526A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270304A1 (en) 2000-07-07 2002-01-21 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
WO2002041918A2 (fr) * 2000-11-24 2002-05-30 Janssen Pharmaceutica N.V. Utilisation d'une combinaison triple contenant un antagoniste 5ht3, un agoniste 5ht4 et un laxatif facilitant le lavement intestinal
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3449928A1 (fr) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Système d'administration d'un composé thérapeutique oral
CN102933207B (zh) 2009-10-30 2018-02-02 Ix生物医药有限公司 快速溶解固体剂型
EP2744445B1 (fr) 2011-08-20 2018-01-31 Advanced Medical Balloons GmbH Cathéter de lavement transanal pour déclencher par intermittence une défécation réflexe coordonnée
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
EP0472502B1 (fr) * 1990-08-24 1995-05-31 Spirig Ag Pharmazeutische Präparate Procédé pour la fabrication de granulés
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (fr) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
JPH10509982A (ja) * 1994-12-01 1998-09-29 サイバス ファーマシューティカル，インコーポレイティド 高等植物から獲得できる粉末ヒドロコロイドゴムを利用するｎｓａｉｄの導入
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
AR014133A1 (es) * 1997-12-19 2001-02-07 Smithkline Beecham Corp Procedimiento para fabricar tabletas de dispersion rapida para administracion oral y una formulacion de dichas tabletas
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode

Also Published As

Publication number Publication date
FR2784899A1 (fr) 2000-04-28
CN1323200A (zh) 2001-11-21
SK2432001A3 (en) 2001-09-11
IS5851A (is) 2001-01-20
DE69929703D1 (de) 2006-04-13
EP1104289A2 (fr) 2001-06-06
FR2784899B1 (fr) 2001-08-17
TR200100361T2 (tr) 2001-06-21
AU2009200403A1 (en) 2009-02-26
EE05054B1 (et) 2008-08-15
CA2338794A1 (fr) 2000-03-02
HU228179B1 (en) 2013-01-28
ES2257869T3 (es) 2006-08-01
JP2002523351A (ja) 2002-07-30
KR100529659B1 (ko) 2005-11-21
YU8701A (sh) 2003-12-31
HRP20010123B1 (en) 2010-11-30
WO2000010526A3 (fr) 2000-09-08
ITMI991826A0 (it) 1999-08-19
HUP0103431A2 (hu) 2002-01-28
CZ300647B6 (cs) 2009-07-08
AU2003248212A1 (en) 2003-10-30
KR20010079668A (ko) 2001-08-22
FR2782454A1 (fr) 2000-02-25
ID28510A (id) 2001-05-31
AU762829B2 (en) 2003-07-03
SK285255B6 (sk) 2006-09-07
BG105257A (en) 2001-11-30
NO20010863D0 (no) 2001-02-20
US20120071537A1 (en) 2012-03-22
ITMI991826A1 (it) 2001-02-19
RS50104B (sr) 2009-01-22
US20080075773A1 (en) 2008-03-27
US20130158092A1 (en) 2013-06-20
US20030236183A1 (en) 2003-12-25
NZ509832A (en) 2003-11-28
HRP20010123A2 (en) 2002-02-28
PL200132B1 (pl) 2008-12-31
IT1314185B1 (it) 2002-12-06
EP1104289B1 (fr) 2006-02-01
PL346764A1 (en) 2002-02-25
NO20010863L (no) 2001-03-26
HK1038179A1 (en) 2002-03-08
IL141236A0 (en) 2002-03-10
CN1589906A (zh) 2005-03-09
PL194069B1 (pl) 2007-04-30
NO328756B1 (no) 2010-05-03
BR9913135A (pt) 2001-05-08
TR200400187T2 (tr) 2006-11-21
AU5623299A (en) 2000-03-14
CZ2001619A3 (en) 2001-05-16
EE200100104A (et) 2002-06-17
HUP0103431A3 (en) 2002-02-28
WO2000010526A2 (fr) 2000-03-02
TR200102259T2 (tr) 2002-06-21
IS2369B (is) 2008-06-15
DK1104289T3 (da) 2006-05-15
FR2799123A1 (fr) 2001-04-06
CA2338794C (fr) 2009-01-20
JP4048024B2 (ja) 2008-02-13
CN1165293C (zh) 2004-09-08
ATE316782T1 (de) 2006-02-15
BG65322B1 (bg) 2008-02-29
AU2006200048A1 (en) 2006-02-02
FR2782454B1 (fr) 2005-12-02
DE69929703T2 (de) 2007-02-22

Similar Documents

Publication Publication Date Title
FR2799123B1 (fr) Composition pharmaceutique orale solide comprenant un agent sensible aux acides et/ou peu soluble en milieu aqueux et un desagregeant, et utilisation de cette composition
ES2133785T3 (es) Inhibidores de metaloproteinasas.
ATE222889T1 (de) Hydroxamsäure-derivate
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
BR9801652A (pt) Resorcinil-triazinas
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
DE69414194T2 (de) Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
IT1291278B1 (it) Preparazione farmaceutica a base di nimesulide per uso topico
OA08130A (fr) Compositions pharmaceutiques ou vétérinaires contenant des dérivés thiosulfonates.
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
MY152490A (en) New oral formulation
HUP9904676A2 (hu) 1-(3-Aminoindazol-5-il)-3-fenilmetil-ciklusos karbamidok és HIV proteáz inhibitorként való alkalmazásuk
CR6300A (es) Nueva formulacion oral
ECSP993104A (es) Nueva formulacion oral

Legal Events

Date Code Title Description
ST Notification of lapse
RN Application for restoration
D3 Ip right revived
PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20